GAMMA Investing’s Relmada Therapeutics RLMD Stock Holding History

GAMMA Investing’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.01K	Buy	533 +492	+1,200%	+$2.41K	﹤0.01%	3952
2026 Q2	$284	Buy	+41	New	+$286	﹤0.01%	4054
2024 Q3	–	Sell	-228	Closed	-$684	–	3645
2024 Q2	$684	Sell	228 -341	-60%	-$1.23K	﹤0.01%	3143
2024 Q1	$2.65K	Hold	569	–	–	﹤0.01%	2659
2023 Q4	$2.24K	Buy	+569	New	+$1.69K	﹤0.01%	2541

Other funds holding RLMD

CV Advisors Aventura, Florida $594M AUM 18% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's RLMD Position: Q3 2026 in Review

GAMMA Investing increased its Relmada Therapeutics (RLMD) stake by 1,200% in Q3 2026, buying an estimated $2.41K and bringing the position to 533 shares worth $2.01K. The position accounts for ﹤0.01% of the portfolio, ranked #3952.

GAMMA Investing first reported a position in RLMD in Q4 2023 and has held it in 5 quarters since. The position peaked at $2.65K in Q1 2024. 3 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.

GAMMA Investing held 533 shares of Relmada Therapeutics worth $2.01K as of Q3 2026.
GAMMA Investing bought 492 Relmada Therapeutics shares in Q3 2026, an estimated $2.41K.
Relmada Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3952 holding.
GAMMA Investing first reported a position in Relmada Therapeutics in Q4 2023 and has held it in 5 quarters since.
GAMMA Investing's Relmada Therapeutics position peaked at $2.65K in Q1 2024.
3 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.